Current reviews in rheumatology 2012: Bulletin of the NYU Hospital for Joint Diseases.
Pub Date: 07/01/2012
Publication: Name: Bulletin of the NYU Hospital for Joint Diseases Publisher: J. Michael Ryan Publishing Co. Audience: Academic Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2012 J. Michael Ryan Publishing Co. ISSN: 1936-9719
Issue: Date: July, 2012 Source Volume: 70 Source Issue: 3
Accession Number: 311498760
Full Text: NYU School of Medicine NYU LANGONE MEDICAL CENTER

Sponsored by the NYU Post-Graduate Medical School

Supported by educational grants from: Amgen, Inc., Human Genome Sciences, Inc., Lilly USA, LLC

Target Audience

Rheumatologists, fellows in rheumatology training, general practitioners interested in rheumatology, as well as ob-gyn specialists, endocrinologists, orthopedic surgeons, physical medicine specialists and radiologists.

Statement of Need

New data has become available related to long-term safety of biologic agents in the treatment of RA. New biologic agents that have become available in 2011 and early 2012 also show a possibly unique safety profile, which practitioners need to be aware of in order to effectively create RA treatment plans. In addition, new ACR RA treatment guidelines have been published in 2012. New RA diagnostic and remission criteria have been proposed over the last year. Practitioners need to be educated about all these new advances in diagnosing and treating patients, which may allow them to identify patients who would benefit from disease-modifying drugs and biologic agents earlier in the disease process. Physician Quality Reporting Initiative has added new measures for physicians to report. These measures regarding RA recommend:

Measuring function, pain and a disease activity measure, in addition to determining the prognosis of a patient based on these measures. These are recommended to be included in routine care. In addition, the "treat to target" paradigm demands that we use outcome measures in routine care. New treatments being developed for systemic lupus erythematosus (SLE) have also been published with different safety profiles. Additionally, new data is now available on older drugs, including long-term safety information.

Educational Objectives

* describe new data on long-term safety and efficacy of current biologic agents as well as new biologics available for treatment of RA

* create strategies to apply the new RA diagnostic and remission criteria in practice

* apply the PQRI measures to streamline treatment of rheumatoid arthritis while incorporating new available agents

* incorporate new published data on treatments for systemic lupus erythematosus (SLE) into treatment decision trees

Accreditation Statement

The NYU Post-Graduate Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The NYU Post-Graduate Medical School designates this enduring material for a maximum of 5 AMA PRA Category 1 Credits[TM]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

To receive up to 5 CME credits, read this supplement, which should take 5 hours of your time, complete the evaluation and post-test and submit to the NYU Post-Graduate Medical School (instructions enclosed). A minimum passing grade of 70% is required.

This activity is valid for credit from October 1, 2012 through December 31, 2012.

Faculty Credentials

Daria Crittenden, MD

Instructor of Medicine

NYU School of Medicine

New York, NY

Stephen Honig, MD

Associate Professor of Medicine

NYU School of Medicine

New York, NY

Philip J. Kahn, MD

Assistant Professor of Pediatrics

NYU School of Medicine

New York, NY

Philip J. Mease, MD

Clinical Professor of Medicine

University of Washington School of Medicine

Seattle, WA

Joan T. Merrill, MD

Adjunct Assistant Professor of Medicine

NYU School of Medicine

New York, NY

Michael H. Pillinger, MD

Associate Professor of Medicine,

Biochemistry and Molecular Pharmacology

NYU School of Medicine

New York, NY

Theodore Pincus, MD

Clinical Professor of Medicine

NYU School of Medicine

New York, NY

Eric Ruderman, MD

Professor of Medicine

Northwestern University Feinberg School of Medicine

Chicago, IL

Jose Scher, MD

Assistant Professor of Medicine

NYU School of Medicine

New York, NY

Ismail Simsek, MD

Associate Professor

Division of Rheumatology

Gulhane School of Medicine

Ankara, Turkey

Gary Solomon, MD

Clinical Associate Professor of Medicine

NYU School of Medicine

New York, NY

Robert Woodrick, MD

Northwestern Memorial Hospital

Chicago, IL

Yusuf Yazici, MD

Assistant Professor of Medicine

NYU School of Medicine

New York, NY

Disclosure Statement

The NYU Post-Graduate Medical School adheres to ACCME Essential Areas and policies, including the Standards for Commercial Support, regarding industry support of continuing medical education. In order to resolve any identified conflicts of interest, disclosure information is provided during the planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships as well as the discussion of unlabeled or unapproved use of any drug, device or procedure by the faculty is listed below.

Daria B. Crittenden, MD--Author--serves as a consultant to Savient Pharmaceuticals, Inc. and is the recipient of research funding from Takeda Pharmaceuticals USA, Inc.

Stephen Honig, MD--Author--reports no relevant financial relationships.

Philip J. Kahn, MD--Author--reports no relevant financial relationships. Dr. Kahn's article will include discussion of the unlabeled or unapproved use of a drug, device or procedure; i.e., many drugs used in the treatment of juvenile rheumatoid arthritis do not have FDA approval.

Philip J. Mease, MD--Author--serves as a consultant to Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Bristol-Myers Squibb, Celgene Corporation, Crescendo Pharmaceuticals, Forest Laboratories, Genentech, Inc., Janssen Biotech, Lilly USA, LLC, Merck & Co., Novartis Pharmaceuticals Corporation, Pfizer, Inc. and UCB, Inc. He serves on the speakers' bureau of Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Bristol-Myers Squibb, Crescendo Pharmaceuticals, Forest Laboratories, Genentech, Inc., Janssen Biotech, Lilly USA, LLC, Pfizer, Inc. and UCB, Inc. He is the recipient of research funding from Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Bristol-Myers Squibb, Celgene Corporation, Crescendo Pharmaceuticals, Forest Laboratories, Genentech, Inc., Janssen Biotech, Lilly USA, LLC, Merck & Co., Novartis Pharmaceuticals Corporation, Pfizer, Inc. and UCB, Inc.

Joan T. Merrill, MD--Author--serves as a consultant to and is the recipient of research funding from Human Genome Sciences, Inc./GlaxoSmithKline, Genentech, Inc./Roche Laboratories, Pfizer, Inc. and Bristol-Myers Squibb. Dr. Merrill's article includes discussion of the unlabeled or unapproved use of a drug, device or procedure; i.e., treatments in development for lupus.

Michael H. Pillinger, MD--Author--serves on the Advisory Board of Savient Pharmaceuticals. He is the recipient of research funding from Takeda Pharmaceuticals USA, Inc. Dr. Pillinger's article includes discussion of the unlabeled or unapproved use of a drug, device or procedure; i.e., studies examining the efficacies of anakinra, canakinumab and rilonacept in gout.

Theodore Pincus, MD--Author--reports no relevant financial relationships.

Eric Ruderman, MD--Author--serves as a consultant to Genentech, Inc./Roche Laboratories. Dr. Ruderman's article includes discussion of the unlabeled or unapproved use of a drug, device or procedure; i.e., unapproved use of interleukin 6 inhibitors in RA and other rheumatic diseases.

Jose Scher, MD--Author--reports no relevant financial relationships.

Ismail Simsek, MD--Author--reports no relevant financial relationships.

Gary Solomon, MD--Author--reports no relevant financial relationships.

Robert Woodrick, MD--Author--reports no relevant financial relationships. Dr. Woodrick's article will include discussion of the unlabeled or unapproved use of a drug, device or procedure; i.e., case reports or small trials of tocilizumab.

Yusuf Yazici, MD--Planner and Author--reports no relevant financial relationships.

Norman Sussman, MD--Associate Dean for Postgraduate Programs and Planner--reports no relevant financial relationships.

The independent reviewer of this activity reports no relevant financial relationships.

Release Date: October 1, 2012

Expiration Date: December 31, 2012
Gale Copyright: Copyright 2012 Gale, Cengage Learning. All rights reserved.